Compare MDV & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MDV | VYGR |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | United States | United States |
| Employees | 9 | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.5M | 203.6M |
| IPO Year | N/A | 2015 |
| Metric | MDV | VYGR |
|---|---|---|
| Price | $17.24 | $3.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $18.00 | $16.50 |
| AVG Volume (30 Days) | 51.5K | ★ 737.1K |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | ★ 7.50% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,135,000.00 |
| Revenue This Year | N/A | $34.04 |
| Revenue Next Year | $8.56 | $7.92 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.80 | $2.88 |
| 52 Week High | $18.96 | $5.55 |
| Indicator | MDV | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 42.12 | 38.00 |
| Support Level | $13.95 | $2.96 |
| Resistance Level | $18.82 | $4.33 |
| Average True Range (ATR) | 0.44 | 0.17 |
| MACD | -0.06 | -0.00 |
| Stochastic Oscillator | 9.80 | 13.16 |
Modiv Industrial Inc is a pioneer in the direct-to-consumer commercial real estate product industry. It provides individual investors access to real estate and real estate-related investments designed to provide both income and long-term growth. The company has invested in single-tenant income-producing properties. Its current business consists of owning, managing, operating, leasing, acquiring, investing in, and disposing of commercial real estate assets utilized for industrial manufacturing, as well as a few non-core assets. All of the company's consolidated revenues are derived from the company's consolidated real estate properties.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.